EUVIMEDEUVIMED entdecken
Crossref

Mitragynine (Kratom)—Withdrawal behaviour and cognitive impairments can be ameliorated by an epigenetic mechanism

Suleiman Yunusa, Christian P Müller, Zurina Hassan iD

British Journal of Pharmacology · 2024

DOI: 10.1111/bph.16352 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2024. Verfasst von Suleiman Yunusa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Drug Research, Universiti Sains Malaysia, Penang, Malaysia. Hauptthemen laut MEDLINE: Secologanin Tryptamine Alkaloids, Substance Withdrawal Syndrome, Epigenesis, Genetic, Cognitive Dysfunction. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: Kementerian Pendidikan Malaysia, Universiti Sains Malaysia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Kratom is a preparation from Mitragyna speciosa , which is used as a natural drug preparation for many purposes around the world. However, an overdose of Kratom may cause addiction‐like problems including aversive withdrawal states resulting in cognitive impairments via unknown mechanisms. Its main psychoactive alkaloid is mitragynine, showing opioid‐like properties. Experimental Approach Here, we analysed the neuropharmacological effects of mitragynine compared with morphine withdrawal in rats and searched for a pharmacological treatment option that may reverse the occurring cognitive deficits that usually aggravate withdrawal. Key Results We found that withdrawal from 14‐day mitragynine (1–10 mg·kg −1 ·day −1 ) treatment caused dose‐dependent behavioural withdrawal signs resembling those of morphine (5 mg·kg −1 ·day −1 ) withdrawal. However, mitragynine (5 and 10 mg·kg −1 ·day −1 ) withdrawal also induced impairments in a passive avoidance task. Mitragynine withdrawal not only reduced hippocampal field excitatory postsynaptic potential (fEPSP) amplitudes in basal synaptic transmission and long‐term potentiation (LTP) but also reduced epigenetic markers, such as histone H3K9 and H4K12 expression. At the same time, it up‐regulates HDAC2 expression. Targeting the epigenetic adaptations with the HDAC inhibitor, SAHA , reversed the effects of mitragynine withdrawal on epigenetic dysregulation, hippocampal input/output curves, paired‐pulse facilitation, LTP and attenuated the cognitive deficit. However, SAHA amplified the effects of morphine withdrawal. Conclusion and Implications The data from this work show that changes in histone expression and downstream hippocampal plasticity may explain mitragynine, but not morphine, withdrawal behaviours and cognitive impairments. Thus, it may provide a new treatment approach for aversive Kratom/mitragynine withdrawal and addiction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Secologanin Tryptamine AlkaloidsSubstance Withdrawal SyndromeEpigenesis, GeneticCognitive DysfunctionAnimalsMaleRatsRats, Sprague-DawleyMorphineMitragynaBehavior, AnimalHippocampusAvoidance LearningDose-Response Relationship, Drug

Stichwörter der Autor:innen

KratomLTPSAHAcognitive deficitshistonesmitragyninemorphine withdrawal

Substanzen

mitragynineSecologanin Tryptamine AlkaloidsMorphine

Autor:innen und Institutionen

  • Centre for Drug Research, Universiti Sains Malaysia, Penang, Malaysia.
  • Department of Pharmacology, Bauchi State University Gadau, Bauchi State, Nigeria.
  • Department of Psychiatry and Psychotherapy, University Clinic, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
  • Institute of Psychopharmacology, Central Institute of Mental Health, Faculty of Medicine Mannheim, University of Heidelberg, Heidelberg, Germany.

ORCID-Profile: Zurina Hassan

Förderung

  • Kementerian Pendidikan Malaysia
  • Universiti Sains Malaysia

Zitieren

APA

Yunusa, S., Müller, C. P., & Hassan, Z. (2024). Mitragynine (Kratom)—Withdrawal behaviour and cognitive impairments can be ameliorated by an epigenetic mechanism. British Journal of Pharmacology. https://doi.org/10.1111/bph.16352

Vancouver

Yunusa S, Müller CP, Hassan Z. Mitragynine (Kratom)—Withdrawal behaviour and cognitive impairments can be ameliorated by an epigenetic mechanism. British Journal of Pharmacology. 2024. doi:10.1111/bph.16352

BibTeX
@article{Yunusa2024,
  author = {Yunusa, Suleiman and Müller, Christian P and Hassan, Zurina},
  title = {Mitragynine (Kratom)—Withdrawal behaviour and cognitive impairments can be ameliorated by an epigenetic mechanism},
  journal = {British Journal of Pharmacology},
  year = {2024},
  doi = {10.1111/bph.16352}
}
Kostenlos starten →